VanEck JP Morgan EM Local Currency Bond ETF vs uniQure N.V. Ordinary Shares — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.95B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: VanEck JP Morgan EM Local Currency Bond ETF is far larger — about 3.4× uniQure N.V. Ordinary Shares's market cap, and VanEck JP Morgan EM Local Currency Bond ETF is more actively traded (3,505,848 versus 3,323,243). Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 40 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| EMLC | QURE | |
|---|---|---|
Market Cap | $4.95B | $1.45B |
Volume | 3,505,848 | 3,323,243 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $70.59 |
52-Week Low | $24.53 | $9.03 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $707.46M |
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.92, up 0.24% on the day, but technical indicators signal a bearish trend with the stock recently hitting a 52-week low. The ETF faces headwinds from dollar strength and Fed rate hike expectations, though some analysts see value in emerging market local currency bonds. Recent dividends of $0.14 and $0.13 were declared for October and August 2026.
Outlook remains cautious as dollar strength pressures emerging market currencies, though diversification benefits and yield potential offer long-term opportunities. Key risks include currency volatility and rising global bond yields, while institutional sentiment appears mixed with technical weakness dominating near-term price action.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →